Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "Zydus"

379 News Found

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia
Clinical Trials | August 31, 2022

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.


Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr
News | August 11, 2022

Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr

The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.


Briefs: Zydus Lifesciences and Kimia Biosciences
News | August 09, 2022

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.


Zydus receives final approval from the USFDA for Ivermectin Cream
Drug Approval | August 04, 2022

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.


Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets
Drug Approval | July 26, 2022

Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets

Bisoprolol Fumarate Tablets are used to treat high blood pressure.


Zydus receives final approval from the USFDA for Efinaconazole Topical Solution
Drug Approval | July 18, 2022

Zydus receives final approval from the USFDA for Efinaconazole Topical Solution

Jublia (Efinaconazole) topical solution, 10% had annual sales of $292 million in the United States according to IQVIA data (IQVIA MAT May 2022).


Zydus gets USFDA’s approval for Empagliflozin, Metformin Hydrochloride tablets
Drug Approval | July 12, 2022

Zydus gets USFDA’s approval for Empagliflozin, Metformin Hydrochloride tablets

Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.


Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes
News | July 10, 2022

Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes

The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes


Zydus receives final approval from USFDA for Lacosamide injection
Drug Approval | July 01, 2022

Zydus receives final approval from USFDA for Lacosamide injection

Lacosamide Injection is used to treat partial-onset seizures.


Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel
Drug Approval | June 07, 2022

Zydus Lifesciences receives USFDA approval for Adapalene and Benzoyl Peroxide Topical Gel

The drug will be manufactured at the group’s topical facility at Ahmedabad